{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:55:27Z","timestamp":1785542127344,"version":"3.56.0"},"reference-count":115,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>The study aimed to compare the effectiveness of various antihypertensive drugs in preventing strokes in hypertensive patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a comprehensive search of PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov to identify randomized controlled trials (RCTs) investigating the efficacy of antihypertensive drugs in stroke prevention from inception until April 2023. A network meta-analysis in a Bayesian framework was performed using the random-effects model.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>This study included 88 RCTs involving 487,076 patients to investigate the effects of antihypertensive drugs in preventing stroke. Among these trials, 58 RCTs specifically focused on comparing the impact of such drugs on hypertensive subjects. In overall population, Angiotensin-converting enzyme inhibitor (ACEIs), Angiotensin receptor blockers (ARBs), Calcium channel blockers (CCBs), and Diuretics (DIs) demonstrated superiority over placebo in in reducing stroke, all-cause mortality, and cardiovascular mortality. CCBs and DIs outperformed \u03b2 adrenergic receptor blockers (BBs), ACEIs, and ARBs in stroke reduction. However, when focusing on hypertensive patients, ACEIs, CCBs, and DIs proved superior to placebo in reducing stroke, all-cause mortality, and cardiovascular mortality. ARBs reduced stroke and all-cause mortality but lacked efficacy in reducing cardiovascular mortality. Of the various CCB subclasses, only the Dihydropyridines displayed efficacy in preventing stroke, all-cause mortality, and cardiovascular mortality. Among diuretic subclasses, thiazide-type DIs exhibited no efficacy in preventing all-cause mortality. ACEIs+CCBs were more effective than ACEIs or ARBs monotherapy in reducing stroke, more effective than ACEIs, ARBs, CCBs, or DIs monotherapy in reducing all-cause mortality, and more effective than ARBs in reducing cardiovascular mortality.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>These findings suggest that ACEIs, dihydropyridine CCBs, and thiazide-like diuretics may provide superior prevention against stroke, all-cause mortality, and cardiovascular mortality in hypertensive patients. Combinations of ACEIs and CCBs may provide enhanced protection of stroke than ACEIs or ARBs monotherapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0313309","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:27:36Z","timestamp":1740162456000},"page":"e0313309","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy of different antihypertensive drug classes for stroke prevention: A network meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"20","author":[{"given":"Ding","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-di","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-3545","authenticated-orcid":true,"given":"Zhong-ning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"5","key":"pone.0313309.ref001","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/jch.13525","article-title":"Blood pressure and stroke: From incidence to outcome","volume":"21","author":"S Lattanzi","year":"2019","journal-title":"J Clin Hypertens"},{"issue":"6","key":"pone.0313309.ref002","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1161\/HYPERTENSIONAHA.120.14653","article-title":"Blood Pressure Management in Stroke.","volume":"76","author":"PB Gorelick","year":"2020","journal-title":"Hypertension"},{"issue":"7","key":"pone.0313309.ref003","article-title":"Adherence to Antihypertensive Medications and Stroke Risk: A Dose\u2010Response Meta\u2010Analysis.","volume":"6","author":"T Xu","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"pone.0313309.ref004","doi-asserted-by":"crossref","first-page":"e044302","DOI":"10.1136\/bmjopen-2020-044302","article-title":"Comparative efficacy and acceptability of different antihypertensive drug classes for cardiovascular disease prevention: protocol for a systematic review and network meta-analysis","volume":"11","author":"H Jussil","year":"2021","journal-title":"BMJ Open"},{"issue":"2","key":"pone.0313309.ref005","doi-asserted-by":"crossref","first-page":"e039597","DOI":"10.1136\/bmjopen-2020-039597","article-title":"Population impact of different hypertension management guidelines based on the prospective population-based Heinz Nixdorf Recall study","volume":"11","author":"J Gronewold","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0313309.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5853\/jos.2020.02698","article-title":"Role of Blood Pressure Management in Stroke Prevention: A Systematic Review and Network Meta-Analysis of 93 Randomized Controlled Trials","volume":"23","author":"XL Zhong","year":"2021","journal-title":"J Stroke"},{"issue":"4","key":"pone.0313309.ref007","doi-asserted-by":"crossref","first-page":"101551","DOI":"10.1016\/j.cpcardiol.2022.101551","article-title":"Incident Stroke Events in Clinical Trials of Antihypertensive Drugs in Cardiovascular Disease Patients: A Network Meta-analysis of Randomized Controlled Trials.","volume":"48","author":"G Wang","year":"2023","journal-title":"Curr Prob Cardiology"},{"issue":"3","key":"pone.0313309.ref008","first-page":"e1003583","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"202118","author":"J Page M","journal-title":"PLoS Med"},{"key":"pone.0313309.ref009","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"key":"pone.0313309.ref010","doi-asserted-by":"crossref","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software.","volume":"41","author":"SR Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"4","key":"pone.0313309.ref011","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis.","volume":"17","author":"A Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"4","key":"pone.0313309.ref012","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2215\/CJN.12940820","article-title":"Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis.","volume":"16","author":"P Ruggenenti","year":"2021","journal-title":"Clin Am Soc Nephro"},{"issue":"21","key":"pone.0313309.ref013","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","article-title":"Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease","volume":"374","author":"EM Lonn","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0313309.ref014","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehu504","article-title":"Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial","volume":"36","author":"Y Sakata","year":"2015","journal-title":"Eur Heart J"},{"issue":"10","key":"pone.0313309.ref015","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","article-title":"Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial","volume":"32","author":"T Ogihara","year":"2014","journal-title":"J Hypertens"},{"issue":"20","key":"pone.0313309.ref016","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy","volume":"369","author":"LF Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"pone.0313309.ref017","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"H-H Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0313309.ref018","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/hr.2012.125","article-title":"Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure","volume":"35","author":"K Asayama","year":"2012","journal-title":"Hypertens Res"},{"issue":"3","key":"pone.0313309.ref019","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/HYPERTENSIONAHA.111.184226","article-title":"Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance","volume":"59","author":"T Muramatsu","year":"2012","journal-title":"Hypertension"},{"issue":"7","key":"pone.0313309.ref020","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/HJH.0b013e3283480db9","article-title":"The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study","volume":"29","author":"T Tillin","year":"2011","journal-title":"J Hypertens"},{"issue":"9647","key":"pone.0313309.ref021","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial","volume":"372","author":"AK Sj\u00f8lie","year":"2008","journal-title":"Lancet"},{"issue":"9767","key":"pone.0313309.ref022","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(11)60104-9","article-title":"The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial","volume":"377","author":"EC Sandset","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"pone.0313309.ref023","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","article-title":"Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial","volume":"29","author":"M Matsuzaki","year":"2011","journal-title":"J Hypertens"},{"issue":"10","key":"pone.0313309.ref024","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"AI Investigators","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0313309.ref025","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes","volume":"364","author":"H Haller","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0313309.ref026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000810","article-title":"The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow\u2010Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation","volume":"3","author":"J Menne","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"pone.0313309.ref027","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ahj.2011.03.028","article-title":"Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"161","author":"FP Brouwers","year":"2011","journal-title":"Am Heart J"},{"issue":"4","key":"pone.0313309.ref028","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/HJH.0b013e32833627c9","article-title":"Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial","volume":"28","author":"L Thijs","year":"2010","journal-title":"J Hypertens"},{"issue":"1","key":"pone.0313309.ref029","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/hr.2010.186","article-title":"Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial","volume":"34","author":"H Narumi","year":"2010","journal-title":"Hypertens Res"},{"issue":"16","key":"pone.0313309.ref030","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events","volume":"362","author":"Group. NS","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0313309.ref031","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehp101","article-title":"Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).","volume":"30","author":"H Kasanuki","year":"2009","journal-title":"Eur Heart J"},{"issue":"11","key":"pone.0313309.ref032","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/hr.2009.139","article-title":"Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature","volume":"32","author":"L Liu","year":"2009","journal-title":"Hypertens Res"},{"issue":"12","key":"pone.0313309.ref033","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"S Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"9644","key":"pone.0313309.ref034","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"S Yusuf","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"pone.0313309.ref035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","article-title":"Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks","volume":"51","author":"T Ogihara","year":"2008","journal-title":"Hypertension"},{"issue":"23","key":"pone.0313309.ref036","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"BM Massie","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0313309.ref037","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/HJH.0b013e3282ff8864","article-title":"The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure\u2013a prospective, randomized, controlled prevention trial of the German Hypertension League","volume":"26","author":"S L\u00fcders","year":"2008","journal-title":"J Hypertens"},{"issue":"23","key":"pone.0313309.ref038","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"K Jamerson","year":"2008","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0313309.ref039","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events","volume":"358","author":"Investigators. O","year":"2008","journal-title":"N Engl J Med"},{"issue":"18","key":"pone.0313309.ref040","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"NS Beckett","year":"2008","journal-title":"N Engl J Med"},{"issue":"9590","key":"pone.0313309.ref041","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Group. AC","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"pone.0313309.ref042","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.","volume":"48","author":"K Norris","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"pone.0313309.ref043","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","article-title":"The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial.","volume":"48","author":"S Julius","year":"2006","journal-title":"Hypertension"},{"issue":"15","key":"pone.0313309.ref044","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of Ramipril on the Incidence of Diabetes","volume":"355","author":"Investigators. DT","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0313309.ref045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1291\/hypres.28.307","article-title":"Efficacy of Candesartan on Outcome in Saitama Trial G. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients","volume":"28","author":"H Suzuki","year":"2005","journal-title":"Hypertens ResApr"},{"issue":"6","key":"pone.0313309.ref046","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention","volume":"36","author":"J Schrader","year":"2005","journal-title":"Stroke"},{"issue":"12","key":"pone.0313309.ref047","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","article-title":"The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients","volume":"23","author":"L Liu","year":"2005","journal-title":"J Hypertens"},{"issue":"9489","key":"pone.0313309.ref048","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"B Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"issue":"9437","key":"pone.0313309.ref049","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"PA Poole-Wilson","year":"2004","journal-title":"Lancet"},{"issue":"18","key":"pone.0313309.ref050","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"SE Nissen","year":"2004","journal-title":"Jama"},{"issue":"7438","key":"pone.0313309.ref051","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","article-title":"Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).","volume":"328","author":"M Marre","year":"2004","journal-title":"BMJ"},{"issue":"8","key":"pone.0313309.ref052","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.hjh.0000133730.47372.4c","article-title":"The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization","volume":"22","author":"H Lithell","year":"2004","journal-title":"J Hypertens"},{"issue":"20","key":"pone.0313309.ref053","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-Converting\u2013Enzyme Inhibition in Stable Coronary Artery Disease","volume":"351","author":"Investigators. TPT","year":"2004","journal-title":"N Engl J Med"},{"issue":"9386","key":"pone.0313309.ref054","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"S Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"pone.0313309.ref055","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting\u2014enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"LM Wing","year":"2003","journal-title":"N Engl J Med"},{"issue":"20","key":"pone.0313309.ref056","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both","volume":"349","author":"MA Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0313309.ref057","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"CJ Pepine","year":"2003","journal-title":"Jama"},{"issue":"9386","key":"pone.0313309.ref058","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"JJV McMurray","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"pone.0313309.ref059","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08037050310009545","article-title":"Treatment of isolated systolic hypertension: the SHELL study results","volume":"12","author":"E Malacco","year":"2003","journal-title":"Blood Press"},{"issue":"9386","key":"pone.0313309.ref060","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"EtOrocewPiscAd. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).","volume":"362","author":"Investigators","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"pone.0313309.ref061","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"CB Granger","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"pone.0313309.ref062","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/00004872-200312000-00030","article-title":"Results of the pilot study for the Hypertension in the Very Elderly Trial","volume":"21","author":"CJ Bulpitt","year":"2003","journal-title":"J Hypertens"},{"issue":"16","key":"pone.0313309.ref063","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"HR Black","year":"2003","journal-title":"Jama"},{"issue":"7","key":"pone.0313309.ref064","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy","volume":"138","author":"T. Berl","year":"2003","journal-title":"Ann Intern Med"},{"issue":"19","key":"pone.0313309.ref065","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis","volume":"106","author":"A Zanchetti","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"pone.0313309.ref066","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"RW Schrier","year":"2002","journal-title":"Kidney Int"},{"issue":"23","key":"pone.0313309.ref067","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","author":"A Officers","year":"2002","journal-title":"Jama"},{"issue":"9335","key":"pone.0313309.ref068","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"K Dickstein","year":"2002","journal-title":"Lancet"},{"issue":"9311","key":"pone.0313309.ref069","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"B Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"issue":"13","key":"pone.0313309.ref070","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1161\/01.CIR.103.13.1721","article-title":"Low-Dose Metoprolol CR\/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness","volume":"103","author":"B Hedblad","year":"2001","journal-title":"Circulation"},{"issue":"9287","key":"pone.0313309.ref071","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"Group. PC","year":"2001","journal-title":"Lancet"},{"issue":"9215","key":"pone.0313309.ref072","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"B Pitt","year":"2000","journal-title":"Lancet"},{"issue":"13","key":"pone.0313309.ref073","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","article-title":"Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events","volume":"102","author":"B Pitt","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"pone.0313309.ref074","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0895-7061(99)00215-0","article-title":"Practitioner\u2019s Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (the PATE-Hypertension Study) in Japan","volume":"13","author":"T. Ogihara","year":"2000","journal-title":"Am J Hypertens"},{"issue":"2","key":"pone.0313309.ref075","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0735-1097(00)00736-1","article-title":"Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease","volume":"36","author":"S MacMahon","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"pone.0313309.ref076","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Heart Outcomes Prevention Evaluation Study I","year":"2000","journal-title":"N Engl J Med"},{"issue":"9227","key":"pone.0313309.ref077","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and \u03b2-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"L Hansson","year":"2000","journal-title":"Lancet"},{"issue":"9227","key":"pone.0313309.ref078","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).","volume":"356","author":"MJ Brown","year":"2000","journal-title":"Lancet"},{"issue":"9153","key":"pone.0313309.ref079","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.","volume":"353","author":"L Hansson","year":"1999","journal-title":"Lancet"},{"issue":"9192","key":"pone.0313309.ref080","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"L Hansson","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"pone.0313309.ref081","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.HYP.34.5.1129","article-title":"Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group","volume":"34","author":"Group. NICSiEHS","year":"1999","journal-title":"Hypertension"},{"issue":"12","key":"pone.0313309.ref082","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00004872-199816120-00016","article-title":"Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.","volume":"16","author":"L Liu","year":"1998","journal-title":"J Hypertens"},{"issue":"10","key":"pone.0313309.ref083","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension","volume":"338","author":"RO Estacio","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0313309.ref084","first-page":"312","article-title":"Prevention and treatment of stroke after hypertension for ten years in Hunan Province","volume":"36","author":"ZH Sun M","year":"1997","journal-title":"Chinese journal of internal medicine"},{"issue":"11","key":"pone.0313309.ref085","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/00004872-199715110-00019","article-title":"Clinical results of the Verapamil in Hypertension and Atherosclerosis Study","volume":"15","author":"EA Rosei","year":"1997","journal-title":"J Hypertens"},{"issue":"10","key":"pone.0313309.ref086","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/00004872-199610000-00013","article-title":"Shanghai trial of nifedipine in the elderly (STONE).","volume":"14","author":"L Gong","year":"1996","journal-title":"J Hypertens"},{"issue":"8875","key":"pone.0313309.ref087","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","author":"Investigators. AIREAS","year":"1993","journal-title":"Lancet"},{"issue":"4","key":"pone.0313309.ref088","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/01.STR.24.4.543","article-title":"Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group","volume":"24","author":"Group. DTTS","year":"1993","journal-title":"Stroke"},{"issue":"6824","key":"pone.0313309.ref089","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results.","volume":"304","author":"MW Party","year":"1992","journal-title":"BMJ"},{"issue":"10","key":"pone.0313309.ref090","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions","volume":"327","author":"Investigators. S","year":"1992","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0313309.ref091","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure","volume":"325","author":"Investigators. S","year":"1991","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0313309.ref092","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP).","volume":"265","author":"Group. SCR","year":"1991","journal-title":"Jama"},{"issue":"8778","key":"pone.0313309.ref093","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","article-title":"Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).","volume":"338","author":"B Dahlof","year":"1991","journal-title":"Lancet"},{"issue":"1","key":"pone.0313309.ref094","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.STR.20.1.4","article-title":"Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study","volume":"20","author":"HM Perry","year":"1989","journal-title":"Stroke"},{"issue":"1","key":"pone.0313309.ref095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000184567","article-title":"The Australian Therapeutic Trial in Mild Hypertension","volume":"47","author":"AE Doyle","year":"1987","journal-title":"Nephron"},{"issue":"6555","key":"pone.0313309.ref096","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","article-title":"Randomised trial of treatment of hypertension in elderly patients in primary care","volume":"293","author":"J Coope","year":"1986","journal-title":"BMJ"},{"issue":"6488","key":"pone.0313309.ref097","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party","volume":"291","author":"MRCW Party","year":"1985","journal-title":"BMJ"},{"issue":"4","key":"pone.0313309.ref098","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","article-title":"Cardiovascular Risk and Risk Factors in a Randomized Trial of Treatment Based on the Beta-Blocker Oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH).","volume":"3","author":"group. Ic","year":"1985","journal-title":"J Hypertens"},{"issue":"8442","key":"pone.0313309.ref099","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(85)91783-0","article-title":"Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial","volume":"1","author":"A Amery","year":"1985","journal-title":"Lancet"},{"issue":"20","key":"pone.0313309.ref100","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1001\/jama.1983.03340200048027","article-title":"A Randomized Trial of Propranolol in Patients With Acute Myocardial Infarction","volume":"250","author":"Group. BHAT","year":"1983","journal-title":"Jama"},{"issue":"5","key":"pone.0313309.ref101","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0002-9343(80)90438-6","article-title":"Treatment of mild hypertension: a five year controlled drug trial. The Oslo study","volume":"69","author":"A. Helgeland","year":"1980","journal-title":"The American journal of medicine"},{"issue":"15","key":"pone.0313309.ref102","doi-asserted-by":"crossref","first-page":"e0256","DOI":"10.1097\/MD.0000000000010256","article-title":"Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus","volume":"97","author":"X lv","year":"2018","journal-title":"Medicine"},{"key":"pone.0313309.ref103","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"2018","author":"YJ Chen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0313309.ref104","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41371-018-0138-y","article-title":"A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension","volume":"33","author":"C Dimou","year":"2018","journal-title":"J Hum Hypertens"},{"issue":"7","key":"pone.0313309.ref105","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","article-title":"Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs\u2014overview and meta-analyses","volume":"33","author":"C Thomopoulos","year":"2015","journal-title":"J Hypertens"},{"issue":"6","key":"pone.0313309.ref106","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/HJH.0b013e3283281254","article-title":"Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients","volume":"27","author":"P Costanzo","year":"2009","journal-title":"J Hypertens"},{"issue":"8","key":"pone.0313309.ref107","first-page":"CD003654","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","author":"ZM Chen N","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0313309.ref108","doi-asserted-by":"crossref","first-page":"e57854","DOI":"10.1371\/journal.pone.0057854","article-title":"The Effects of Calcium Channel Blockers in the Prevention of Stroke in Adults with Hypertension: A Meta-Analysis of Data from 273,543 Participants in 31 Randomized Controlled Trials","volume":"8","author":"GJ Chen","year":"2013","journal-title":"PLoS ONE"},{"issue":"2","key":"pone.0313309.ref109","doi-asserted-by":"crossref","first-page":"e1921618","DOI":"10.1001\/jamanetworkopen.2019.21618","article-title":"Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications","volume":"3","author":"J Wei","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0313309.ref110","first-page":"22","article-title":"Epidemiology, pathophysiology, and treatment of hypertension in ischaemic stroke patients","author":"NF Hisham","year":"2013","journal-title":"J Stroke Cerebrovasc"},{"issue":"12","key":"pone.0313309.ref111","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ajh\/hpv050","article-title":"Cardioprotective Effect of Thiazide-Like Diuretics: A Meta-Analysis","volume":"28","author":"P Chen","year":"2015","journal-title":"Am J Hypertens"},{"issue":"4","key":"pone.0313309.ref112","article-title":"First-line drugs for hypertension","volume":"2018","author":"JM Wright","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"pone.0313309.ref113","article-title":"Beta-blockers for hypertension.","volume":"2017","author":"CS Wiysonge","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"pone.0313309.ref114","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","article-title":"Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials","volume":"38","author":"C Thomopoulos","year":"2020","journal-title":"J Hypertens"},{"issue":"5","key":"pone.0313309.ref115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/HJH.0000000000002759","article-title":"Monotherapy vs combination treatments of different complexity: a meta-analysis of blood pressure lowering randomized outcome trials","volume":"39","author":"C Thomopoulos","year":"2021","journal-title":"J Hypertens"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0343104","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:28:32Z","timestamp":1740162512000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313309"}},"subtitle":[],"editor":[{"given":"Amir Hossein","family":"Behnoush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":115,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313309","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}